[go: up one dir, main page]

PT4249512T - Formulação de anticorpos estáveis - Google Patents

Formulação de anticorpos estáveis

Info

Publication number
PT4249512T
PT4249512T PT231779737T PT23177973T PT4249512T PT 4249512 T PT4249512 T PT 4249512T PT 231779737 T PT231779737 T PT 231779737T PT 23177973 T PT23177973 T PT 23177973T PT 4249512 T PT4249512 T PT 4249512T
Authority
PT
Portugal
Prior art keywords
antibody formulation
stable antibody
stable
formulation
antibody
Prior art date
Application number
PT231779737T
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PT4249512T publication Critical patent/PT4249512T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PT231779737T 2017-04-06 2018-03-23 Formulação de anticorpos estáveis PT4249512T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762482270P 2017-04-06 2017-04-06

Publications (1)

Publication Number Publication Date
PT4249512T true PT4249512T (pt) 2025-07-31

Family

ID=62028099

Family Applications (2)

Application Number Title Priority Date Filing Date
PT187193388T PT3606504T (pt) 2017-04-06 2018-03-23 Formulação de anticorpos estáveis
PT231779737T PT4249512T (pt) 2017-04-06 2018-03-23 Formulação de anticorpos estáveis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT187193388T PT3606504T (pt) 2017-04-06 2018-03-23 Formulação de anticorpos estáveis

Country Status (31)

Country Link
US (2) US11603407B2 (pt)
EP (3) EP4628509A2 (pt)
JP (1) JP7229171B2 (pt)
KR (1) KR102667484B1 (pt)
CN (1) CN110709062B (pt)
AR (1) AR111455A1 (pt)
AU (1) AU2018247501B2 (pt)
BR (1) BR112019020246A2 (pt)
CA (1) CA3059087A1 (pt)
CL (1) CL2019002828A1 (pt)
CO (1) CO2019011021A2 (pt)
DK (2) DK3606504T5 (pt)
EA (1) EA201992377A1 (pt)
ES (1) ES2955062T3 (pt)
FI (2) FI3606504T3 (pt)
HR (1) HRP20231282T1 (pt)
HU (1) HUE063509T2 (pt)
IL (1) IL269499B2 (pt)
LT (2) LT4249512T (pt)
MA (1) MA49043B1 (pt)
MX (1) MX2019011207A (pt)
MY (1) MY198318A (pt)
PH (1) PH12019502123A1 (pt)
PL (1) PL3606504T3 (pt)
PT (2) PT3606504T (pt)
RS (2) RS64680B1 (pt)
SG (2) SG11201908540PA (pt)
SI (2) SI3606504T1 (pt)
SM (2) SMT202500308T1 (pt)
TW (1) TWI795396B (pt)
WO (1) WO2018187057A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
MD3394103T2 (ro) 2015-12-22 2023-11-30 Regeneron Pharma Combinație de anticorpi anti-PD-1 și anticorpi bispecifici anti-CD20/anti-CD3 pentru tratamentul cancerului
EP3423157A1 (en) 2016-03-03 2019-01-09 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
IL321717A (en) 2017-02-21 2025-08-01 Regeneron Pharma Anti-PD-1 antibodies for the treatment of lung cancer
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
SG11201909955XA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
EP3876978A4 (en) 2018-11-07 2022-09-28 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
LT3880186T (lt) 2018-11-14 2024-06-10 Regeneron Pharmaceuticals, Inc. Pd-1 inhibitorių skyrimas į pažeidimo vietą odos vėžiui gydyti
NZ778977A (en) 2019-02-18 2025-06-27 Lilly Co Eli Therapeutic antibody formulation
CA3137361A1 (en) 2019-02-28 2020-09-03 Regeneron Pharmaceuticals, Inc. Administration of pd-1 inhibitors for treating skin cancer
EP3935085A1 (en) 2019-03-06 2022-01-12 Regeneron Pharmaceuticals, Inc. Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
US20200369760A1 (en) * 2019-05-24 2020-11-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-angptl3 antibodies
WO2021023267A1 (zh) * 2019-08-07 2021-02-11 信达生物制药(苏州)有限公司 包含抗pd-1/her2双特异性抗体的制剂及其制备方法和用途
CN114786719A (zh) * 2019-10-02 2022-07-22 阿拉玛布治疗学股份有限公司 抗-连接蛋白抗体制剂
US20210128710A1 (en) * 2019-11-04 2021-05-06 Inovio Pharmaceuticals, Inc. Combination therapy to treat brain cancer
KR20210059646A (ko) * 2019-11-15 2021-05-25 삼성바이오에피스 주식회사 항체 의약품용 액상 조성물
WO2021123202A1 (en) 2019-12-20 2021-06-24 Formycon Ag Formulations of anti-pd1 antibodies
MX2022008320A (es) 2020-01-08 2022-10-21 argenx BV Métodos para tratar trastornos de pénfigo.
KR20210097882A (ko) * 2020-01-30 2021-08-10 삼성바이오에피스 주식회사 안정한 항-pd-1 항체 약제학적 제제
CN115666522B (zh) * 2020-03-18 2025-05-27 Gi医诺微新 包含il-2蛋白和cd80蛋白的融合蛋白制剂
MX2022014974A (es) 2020-05-26 2023-01-11 Boehringer Ingelheim Int Anticuerpos anti-pd-1.
IL298273A (en) 2020-05-26 2023-01-01 Regeneron Pharma Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab
KR20230026446A (ko) * 2020-06-19 2023-02-24 사이노셀테크 엘티디. 재조합 항-pd-1 단일클론 항체를 위한 안정한 제형
EP4175669A1 (en) * 2020-07-03 2023-05-10 CSL Innovation Pty Ltd High concentration formulation of factor xii antigen binding proteins
AU2021316119A1 (en) * 2020-07-31 2023-03-02 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
IL300704A (en) 2020-08-18 2023-04-01 Omeros Corp Monoclonal antibodies, preparations and methods for detecting complement factor D
JP2023540217A (ja) 2020-08-26 2023-09-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｄ－１阻害剤を投与することによりがんを処置する方法
EP4208258A1 (en) 2020-09-03 2023-07-12 Regeneron Pharmaceuticals, Inc. Methods of treating cancer pain by administering a pd-1 inhibitor
CA3192509A1 (en) 2020-09-24 2022-03-31 Yogita Krishnamachari Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof
MX2023009279A (es) 2021-02-11 2023-10-02 Regeneron Pharma Metodos de tratamiento de cancer mediante la administracion de un inhibidor de pd-1 como neoadyuvante.
JP2024507866A (ja) 2021-02-23 2024-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｄ－１阻害剤を投与することにより肺がんを処置する方法
IL305776A (en) 2021-03-23 2023-11-01 Regeneron Pharma Methods of treating cancer in patients with suppression or failure of the immune system through the administration of a PD-1 inhibitor
MX2023014616A (es) 2021-06-23 2024-01-30 Formycon Ag Formulaciones de anticuerpos anti-pd1.
JP2024531192A (ja) 2021-08-13 2024-08-29 イノビオ ファーマシューティカルズ，インコーポレイティド 脳がんを治療するための併用療法
TW202342098A (zh) * 2022-04-14 2023-11-01 瑞士商百濟神州瑞士有限責任公司 含有ｐｄ－１抗體的穩定高濃度氯化鈉配製物及其使用方法
TW202345902A (zh) * 2022-04-14 2023-12-01 瑞士商百濟神州瑞士有限責任公司 含有ｐｄ－１抗體的穩定高濃度精胺酸配製物及其使用方法
EP4540282A1 (en) 2022-06-15 2025-04-23 argenx BV Fcrn/antigen-binding molecules and methods of use
AU2023413756A1 (en) 2022-12-21 2025-07-10 Formycon Ag Formulations of anti-pd1 antibodies
AU2024221025A1 (en) 2023-02-16 2025-08-21 Sun Pharmaceutical Industries Limited Stable protein compositions of anti-pd1 antibody
WO2024223299A2 (en) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
US20250108173A1 (en) 2023-10-02 2025-04-03 Regeneron Pharmaceuticals, Inc. Drug delivery device safety system
WO2025117889A2 (en) 2023-11-30 2025-06-05 Regeneron Pharmaceuticals, Inc. Methods of treating cancer by administering a combination therapy including a neoadjuvant pd-1 inhibitor

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
DK1210428T3 (en) 1999-08-23 2015-06-15 Dana Farber Cancer Inst Inc PD-1, a receptor for B7-4 AND USE THEREOF
PL362804A1 (en) 1999-08-23 2004-11-02 Dana-Farber Cancer Institute Novel b7-4 molecules and uses therefor
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
AU7309601A (en) 2000-06-28 2002-01-08 Genetics Inst Pd-l2 molecules: novel pd-1 ligands and uses therefor
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
JP4488740B2 (ja) 2001-11-13 2010-06-23 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 免疫細胞活性化を調節する作用剤およびその使用方法
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
JP2004104681A (ja) 2002-09-12 2004-04-02 Renesas Technology Corp 入力バッファ回路
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
CA2580981C (en) 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Stabilized human igg4 antibodies
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
CN117534755A (zh) 2005-05-09 2024-02-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
HRP20080028A2 (en) 2005-06-20 2009-08-31 Medarex Cd19 antibodies and their uses
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
US8216996B2 (en) 2006-03-03 2012-07-10 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of cell surface functional molecule
AU2007254831B2 (en) 2006-06-02 2012-03-22 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
ES2437327T3 (es) 2007-06-18 2014-01-10 Merck Sharp & Dohme B.V. Anticuerpos para el receptor PD-1 humano de muerte programada
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US9243052B2 (en) 2007-08-17 2016-01-26 Daniel Olive Method for treating and diagnosing hematologic malignancies
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
WO2009101611A1 (en) 2008-02-11 2009-08-20 Curetech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
US9181342B2 (en) 2008-09-12 2015-11-10 Isis Innovation Limited PD-1 specific antibodies and uses thereof
EP2342229A1 (en) 2008-09-12 2011-07-13 ISIS Innovation Limited Pd-1 specific antibodies and uses thereof
EP3133086B1 (en) 2008-09-26 2018-08-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
KR20240093808A (ko) 2008-12-09 2024-06-24 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
ES2681214T3 (es) 2009-09-30 2018-09-12 Memorial Sloan-Kettering Cancer Center Inmunoterapia de combinación para el tratamiento del cáncer
MX359551B (es) 2009-11-24 2018-10-02 Medimmune Ltd Agentes de union diana contra b7-h1.
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
KR102283195B1 (ko) 2010-02-08 2021-07-29 리제너론 파마슈티칼스 인코포레이티드 일반적인 경쇄 마우스
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
US9029315B2 (en) 2010-11-11 2015-05-12 The University Of Hong Kong Soluble PD-1 variants, fusion constructs, and uses thereof
WO2012135408A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
CN103596585A (zh) * 2011-04-07 2014-02-19 葛兰素史密斯克莱有限责任公司 粘度降低的制剂
WO2012145493A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
KR20140041598A (ko) 2011-07-24 2014-04-04 큐어 테크 리미티드 인간화된 면역조절 모노클로날 항체의 변이체
PE20141693A1 (es) 2011-08-01 2014-11-24 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1e inhibidores de mek
CN108771655A (zh) 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
SG11201402603WA (en) 2011-11-28 2014-06-27 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
GB201120527D0 (en) 2011-11-29 2012-01-11 Ucl Business Plc Method
US20140370012A1 (en) 2012-01-27 2014-12-18 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
EP3511343A1 (en) 2012-05-04 2019-07-17 Dana Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
US20130303250A1 (en) 2012-05-11 2013-11-14 Ryan Moore Method of Playing a Card Game
SG11201407190TA (en) 2012-05-15 2014-12-30 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
EP3556776A1 (en) 2012-05-31 2019-10-23 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonists and vegf antagonists
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
NZ631405A (en) 2012-10-02 2017-01-27 Bristol Myers Squibb Co Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
EP2911669B1 (en) 2012-10-26 2024-04-10 The University of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
RU2718988C2 (ru) 2013-02-22 2020-04-15 Куревак Аг Комбинация противораковой рнк-вакцины и ингибитора пути pd-1 и ее применение
LT2970473T (lt) 2013-03-14 2017-10-25 Bristol-Myers Squibb Company Dr5 agonisto ir anti-pd-1 antagonisto derinys ir naudojimo būdai
KR102389677B1 (ko) 2013-03-15 2022-04-21 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
SI2992017T1 (sl) 2013-05-02 2021-04-30 Anaptysbio, Inc. Protitelesa, usmerjena proti programirani smrti-1 (PD-1)
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
HRP20201404T1 (hr) 2013-07-16 2020-11-27 F. Hoffmann - La Roche Ag Postupci liječenja raka primjenom pd-1 osno vezujućeg antagonista i inhibitora tigita
EP3027210A1 (en) 2013-08-02 2016-06-08 Aduro Biotech Holdings, Europe B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
ES2827679T3 (es) 2013-08-20 2021-05-24 Merck Sharp & Dohme Tratamiento del cáncer con una combinación de un antagonista de PD-1 y dinaciclib
EP4249065A3 (en) 2013-09-20 2023-11-15 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CA2925310C (en) 2013-09-27 2022-12-06 Genentech, Inc. Anti-pdl1 antibody formulations
AU2014354384B2 (en) * 2013-11-29 2018-11-08 Ares Trading S.A. A liquid formulation of a fusion protein comprising TNFR and Fc region
SI3192812T1 (sl) 2013-12-17 2020-10-30 Genentech, Inc. Anti-CD3 protitelesa in načini uporabe
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
KR102513870B1 (ko) 2014-10-14 2023-03-23 노파르티스 아게 Pd-l1에 대한 항체 분자 및 그의 용도
KR20170135860A (ko) 2015-03-13 2017-12-08 싸이톰스 테라퓨틱스, 인크. 항-pdl1 항체, 활성화 가능한 항-pdl1 항체, 및 이들의 사용 방법
EA201792273A1 (ru) 2015-04-17 2018-04-30 Бристол-Маерс Сквибб Компани Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
MD3394103T2 (ro) 2015-12-22 2023-11-30 Regeneron Pharma Combinație de anticorpi anti-PD-1 și anticorpi bispecifici anti-CD20/anti-CD3 pentru tratamentul cancerului
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation

Also Published As

Publication number Publication date
IL269499A (en) 2019-11-28
CN110709062B (zh) 2024-03-08
SI3606504T1 (sl) 2023-10-30
EP4249512A2 (en) 2023-09-27
SMT202300310T1 (it) 2023-11-13
EP4249512A3 (en) 2023-11-22
EP4628509A2 (en) 2025-10-08
RS67103B1 (sr) 2025-09-30
US20190040137A1 (en) 2019-02-07
MA49043A (fr) 2020-02-12
WO2018187057A1 (en) 2018-10-11
TWI795396B (zh) 2023-03-11
US20230183348A1 (en) 2023-06-15
US11603407B2 (en) 2023-03-14
EA201992377A1 (ru) 2020-02-17
LT4249512T (lt) 2025-09-10
TW201900210A (zh) 2019-01-01
MA49043B1 (fr) 2023-11-30
AU2018247501B2 (en) 2025-02-27
MY198318A (en) 2023-08-23
DK3606504T5 (da) 2024-09-02
PT3606504T (pt) 2023-09-04
CO2019011021A2 (es) 2020-01-17
AU2018247501A1 (en) 2019-10-31
ES2955062T3 (es) 2023-11-28
SG10202111008QA (en) 2021-11-29
BR112019020246A2 (pt) 2020-05-12
JP2020516608A (ja) 2020-06-11
CA3059087A1 (en) 2018-10-11
NZ757874A (en) 2025-02-28
FI3606504T3 (fi) 2023-08-23
KR102667484B1 (ko) 2024-05-22
EP4249512B1 (en) 2025-07-23
DK3606504T3 (en) 2023-09-04
PH12019502123A1 (en) 2020-06-29
EP3606504A1 (en) 2020-02-12
CN110709062A (zh) 2020-01-17
FI4249512T3 (fi) 2025-09-04
PL3606504T3 (pl) 2024-01-08
IL269499B1 (en) 2024-08-01
IL269499B2 (en) 2024-12-01
SG11201908540PA (en) 2019-10-30
CL2019002828A1 (es) 2019-12-27
JP7229171B2 (ja) 2023-02-27
RS64680B1 (sr) 2023-11-30
HUE063509T2 (hu) 2024-01-28
EP3606504B1 (en) 2023-07-19
LT3606504T (lt) 2023-09-11
DK4249512T3 (en) 2025-08-18
HRP20231282T1 (hr) 2024-02-02
AR111455A1 (es) 2019-07-17
MX2019011207A (es) 2019-12-11
KR20190134743A (ko) 2019-12-04
SI4249512T1 (sl) 2025-09-30
SMT202500308T1 (it) 2025-09-12

Similar Documents

Publication Publication Date Title
IL269499A (en) Stable antibody formulation
IL250363A0 (en) Stable formulation of anti-il-4r-alpha antibody
IL248802B (en) Antibody formulation
ZA202006263B (en) Antibody formulation
IL274139A (en) Sprayable formulation
IL271416A (en) Bispecific antibody formulation
IL282813A (en) Formulation of antibodies
SG11202103064YA (en) Antibody formulation
IL274719A (en) formulation
GB201701239D0 (en) Novel formulation
GB201713724D0 (en) Formulation
GB201706969D0 (en) Formulation
GB201719464D0 (en) Formulation
ZA202006262B (en) Stable antibody formulation
HK40109865A (en) Stable anti-osmr antibody formulation
HK40099005A (en) Stable antibody formulation
HK40025055A (zh) 稳定的抗osmr抗体制剂
GB2568045B (en) Formulation
GB201720808D0 (en) Formulation
GB201719411D0 (en) Novel formulation
GB201719377D0 (en) Novel formulation
GB201719410D0 (en) Novel formulation
GB201717131D0 (en) Novel formulation
GB201702058D0 (en) Formulation
HK1235313A1 (en) Stable anti-il-4r-alpha antibody formulation